T. Kishimoto, MD, PhD, Associate Professor. S. Wada, MD, Urologist.
Clinical Studies on Cell-mediated Immunity in Patients with Urinary Bladder Carcinoma: Blastogenic Response, Interleukin-2 Production and Interferon-y Production of Lymphocytes
Version of Record online: 26 NOV 2008
© 1990 British Journal of Urology
British Journal of Urology
Volume 65, Issue 4, pages 333–338, April 1990
How to Cite
IKEMOTO, S., KISHIMOTO, T., WADA, S., NISHIO, S. and MAEKAWA, M. (1990), Clinical Studies on Cell-mediated Immunity in Patients with Urinary Bladder Carcinoma: Blastogenic Response, Interleukin-2 Production and Interferon-y Production of Lymphocytes. British Journal of Urology, 65: 333–338. doi: 10.1111/j.1464-410X.1990.tb14751.x
S. Ikemoto, MD, Urologist.
- Issue online: 26 NOV 2008
- Version of Record online: 26 NOV 2008
- Accepted for publication 14 July 1989
Summary— Patients with advanced malignant neoplasms have a variety of abnormal lymphocyte functions. We examined the PHA blastogenic response, interleukin-2 (IL-2) production and interferon-y (IFN-y) production of lymphocytes in 39 bladder cancer patients and 20 control subjects. Correlation between these parameters was also studied. IL-2 production was measured by 3H-thymidine-labelled CTLL-2 assay, and IFN-γ production was measured by immunoradiometric assay using 2 mouse monoclonal antibodies. As a result, in high stage bladder cancer patients, the PHA blastogenic response, IL-2 production and IFN-γ production were impaired. However, these parameters were not significantly different between low stage bladder cancer patients and control subjects. There was a significant correlation between the PHA blastogenic response and IL-2 production but no significant correlation between the PHA blastogenic response and IFN-γ production.